New Delhi, May 16: Leading biotechnology company Shantha Biotechnics said on Friday that it has developed recombinant interferon technology for cancer and viral hepatitis patients for which it is seeking a patent. Shanferon', a recombinant interferon is used for patients suffering from chronic myeloid leukemia, chronic viral hepatitis and other cancers, a company release said here.
Shantha has applied for patent in US and Europe.
It has recently received an award from the Union Government for developing and commercially marketing this technology, it added. Bureau Report